Khang Luu

Mr. Khang Luu

National University of Singapore
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2020 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
Khang LuuKhang Luu
Khang Luu
ZSZhe Shao
Zhe Shao
HSHerbert Schwarz
Herbert Schwarz

9 February 2021 in Cells
Verified
Journal Article
Open access
PDF file
Khang LuuKhang Luu
Khang Luu
MPMugdha Patwardhan
Mugdha Patwardhan
QZQun Zeng
Qun Zeng
SWStina L. Wickström
Stina L. Wickström
ALAndreas Lundqvist
Andreas Lundqvist
HSHerbert Schwarz
Herbert Schwarz
CD137 is a costimulatory molecule expressed on activated T cells. CD137 ligand (CD137L) is expressed by antigen presenting cells (APC), which use the CD137—CD137L system to enhance immune responses. It was, therefore, surprising to discover CD137 expression on regulatory T cells (Treg). The function of CD137 in Treg are controversial. While some studies report that CD137 signalling converts Treg to effector T cells (Teff), other studies find that CD137-expressing Treg display a stronger inhibitory activity than CD137- Treg. Here, we describe that CD137 on Treg binds to CD137L on APC, upon which one of the two molecules is transferred via trogocytosis to the other cell, where CD137—CD137L forms a complex that is internalized and deprives APC of the immune-stimulatory CD137L. Truncated forms of CD137 that lack the cytoplasmic domain of CD137 are also able to downregulate CD137L, demonstrating that CD137 signalling is not required. Comparable data have been obtained with human and murine cells, indicating that this mechanism is evolutionarily conserved. These data describe trogocytosis of CD137 and CD137L as a new mechanism employed by Treg to control immune responses by downregulating the immunostimulatory CD137L on APC.

1 June 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
Khang LuuKhang Luu
Khang Luu
HSHerbert Schwarz
Herbert Schwarz
ALAndreas Lundqvist
Andreas Lundqvist
The discovery of immune checkpoints highlights the complexity of T cell signalling during an immune response. Upon activation, T cells express several molecules to regulate their function and to prevent overactivation. B7 homolog 7 (B7-H7) is expressed in tumours and associated with a worse prognosis. However, conflicting data regarding its function suggest that it can be both stimulatory and inhibitory. In this study we report that B7-H7 is also expressed on T cells upon cross-linking of CD3 and CD28 and that additional stimulationviaCD137 further enhances the expression of B7-H7. B7-H7 is preferentially expressed on exhausted Th1 and Tc1 cells with an impaired secretion of TNF-α and IFN-γ. Blockade of B7-H7 with its natural receptor, recombinant CD28H, enhances T cell proliferation and activation. Thus, B7-H7 represents another target for immunotherapy and a biomarker to select for active effector T cells with relevance for adoptive cell transfer therapy.

3 November 2019 in OncoImmunology
Verified
Journal Article
Open access
Khang LuuKhang Luu
Khang Luu
ENEmily Nickles
Emily Nickles
HSHerbert Schwarz
Herbert Schwarz
New evidence indicates the importance of CD137 for controlling Epstein-Barr virus (EBV) infections. (1) Mutations in CD137 predispose to EBV-associated diseases. (2) EBV induces ectopic CD137 expression, thereby activating a negative feed-back regulation and reducing T cell costimulation. These findings suggest CD137 agonists as new treatments for EBV-associated diseases.